IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.
Free access to all Sound Bites content
Published 1 week
Medical Professional
MARIPOSA dose interruption/reduction efficacy
Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)
Gabriela Hobbs, MD
Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)
Eytan Stein, MD
Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)
Wade Iams, MD
What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)
Rahul Banerjee, MD
Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)
Gabriela Hobbs, MD
Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)
Eytan Stein, MD